Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis
Identifieur interne : 000E69 ( Main/Exploration ); précédent : 000E68; suivant : 000E70Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis
Auteurs : Eleftherios Pelechas [Grèce] ; Paraskevi V. Voulgari [Grèce] ; Alexandros A. Drosos [Grèce]Source :
- Therapeutics and Clinical Risk Management [ 1176-6336 ] ; 2019.
Abstract
Rheumatoid arthritis (RA) is an autoimmune disease that is characterised by synovial inflammation and progressive joint disorder with significant pain and stiffness, which lead to functional disability and systemic complications if left untreated. Although methotrexate (MTX) is the cornerstone in the RA therapy, it is ineffective or intolerable in up to 50% of patients. In addition, tumour necrosis factor (TNF) inhibitors which are regarded as the standard of care for those patients, have not been proven a panacea creating a therapeutic gap. In this direction, other cytokines such as the interleukin (IL)-6 in combination with MTX or as monotherapy have been approved. Sarilumab has already been approved for the treatment of moderate to severe RA, but more studies are on their way including polymyalgia rheumatica, giant cell arteritis, juvenile idiopathic arthritis, and indolent systemic mastocytosis. On the other hand, a study was prematurely discontinued after approximately 1.5 years, when the ankylosing spondylitis development program was discontinued due to lack of efficacy. Regarding safety, efficacy and tolerability of the molecule, three pivotal clinical trials have established sarilumab as one of the safe and efficacious choices for the treatment of RA (mobility, target and monarch trials). Significant decreases in progression of structural damage have been demonstrated. Infections and neutropenia are two of the most common adverse events. Sarilumab is beyond any doubt another molecule that can be added to the clinicians’ armamentarium for the treatment of patients with moderate to severe RA with a good safety and efficacy profile.
Url:
DOI: 10.2147/TCRM.S167452
PubMed: 31564885
PubMed Central: 6732515
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000D91
- to stream Pmc, to step Curation: 000D91
- to stream Pmc, to step Checkpoint: 000A47
- to stream PubMed, to step Corpus: 000273
- to stream PubMed, to step Curation: 000273
- to stream PubMed, to step Checkpoint: 000543
- to stream Ncbi, to step Merge: 002391
- to stream Ncbi, to step Curation: 002391
- to stream Ncbi, to step Checkpoint: 002391
- to stream Main, to step Merge: 000E69
- to stream Main, to step Curation: 000E69
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis</title><author><name sortKey="Pelechas, Eleftherios" sort="Pelechas, Eleftherios" uniqKey="Pelechas E" first="Eleftherios" last="Pelechas">Eleftherios Pelechas</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina</institution>,<addr-line>Ioannina</addr-line>,<country>Greece</country></nlm:aff><country xml:lang="fr">Grèce</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Voulgari, Paraskevi V" sort="Voulgari, Paraskevi V" uniqKey="Voulgari P" first="Paraskevi V" last="Voulgari">Paraskevi V. Voulgari</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina</institution>,<addr-line>Ioannina</addr-line>,<country>Greece</country></nlm:aff><country xml:lang="fr">Grèce</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Drosos, Alexandros A" sort="Drosos, Alexandros A" uniqKey="Drosos A" first="Alexandros A" last="Drosos">Alexandros A. Drosos</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina</institution>,<addr-line>Ioannina</addr-line>,<country>Greece</country></nlm:aff><country xml:lang="fr">Grèce</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31564885</idno><idno type="pmc">6732515</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732515</idno><idno type="RBID">PMC:6732515</idno><idno type="doi">10.2147/TCRM.S167452</idno><date when="2019">2019</date><idno type="wicri:Area/Pmc/Corpus">000D91</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000D91</idno><idno type="wicri:Area/Pmc/Curation">000D91</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000D91</idno><idno type="wicri:Area/Pmc/Checkpoint">000A47</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000A47</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:31564885</idno><idno type="wicri:Area/PubMed/Corpus">000273</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000273</idno><idno type="wicri:Area/PubMed/Curation">000273</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000273</idno><idno type="wicri:Area/PubMed/Checkpoint">000543</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000543</idno><idno type="wicri:Area/Ncbi/Merge">002391</idno><idno type="wicri:Area/Ncbi/Curation">002391</idno><idno type="wicri:Area/Ncbi/Checkpoint">002391</idno><idno type="wicri:doubleKey">1176-6336:2019:Pelechas E:clinical:evaluation:of</idno><idno type="wicri:Area/Main/Merge">000E69</idno><idno type="wicri:Area/Main/Curation">000E69</idno><idno type="wicri:Area/Main/Exploration">000E69</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis</title><author><name sortKey="Pelechas, Eleftherios" sort="Pelechas, Eleftherios" uniqKey="Pelechas E" first="Eleftherios" last="Pelechas">Eleftherios Pelechas</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina</institution>,<addr-line>Ioannina</addr-line>,<country>Greece</country></nlm:aff><country xml:lang="fr">Grèce</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Voulgari, Paraskevi V" sort="Voulgari, Paraskevi V" uniqKey="Voulgari P" first="Paraskevi V" last="Voulgari">Paraskevi V. Voulgari</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina</institution>,<addr-line>Ioannina</addr-line>,<country>Greece</country></nlm:aff><country xml:lang="fr">Grèce</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Drosos, Alexandros A" sort="Drosos, Alexandros A" uniqKey="Drosos A" first="Alexandros A" last="Drosos">Alexandros A. Drosos</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina</institution>,<addr-line>Ioannina</addr-line>,<country>Greece</country></nlm:aff><country xml:lang="fr">Grèce</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></analytic><series><title level="j">Therapeutics and Clinical Risk Management</title><idno type="ISSN">1176-6336</idno><idno type="eISSN">1178-203X</idno><imprint><date when="2019">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Abstract</title><p>Rheumatoid arthritis (RA) is an autoimmune disease that is characterised by synovial inflammation and progressive joint disorder with significant pain and stiffness, which lead to functional disability and systemic complications if left untreated. Although methotrexate (MTX) is the cornerstone in the RA therapy, it is ineffective or intolerable in up to 50% of patients. In addition, tumour necrosis factor (TNF) inhibitors which are regarded as the standard of care for those patients, have not been proven a panacea creating a therapeutic gap. In this direction, other cytokines such as the interleukin (IL)-6 in combination with MTX or as monotherapy have been approved. Sarilumab has already been approved for the treatment of moderate to severe RA, but more studies are on their way including polymyalgia rheumatica, giant cell arteritis, juvenile idiopathic arthritis, and indolent systemic mastocytosis. On the other hand, a study was prematurely discontinued after approximately 1.5 years, when the ankylosing spondylitis development program was discontinued due to lack of efficacy. Regarding safety, efficacy and tolerability of the molecule, three pivotal clinical trials have established sarilumab as one of the safe and efficacious choices for the treatment of RA (mobility, target and monarch trials). Significant decreases in progression of structural damage have been demonstrated. Infections and neutropenia are two of the most common adverse events. Sarilumab is beyond any doubt another molecule that can be added to the clinicians’ armamentarium for the treatment of patients with moderate to severe RA with a good safety and efficacy profile.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><affiliations><list><country><li>Grèce</li></country></list><tree><country name="Grèce"><noRegion><name sortKey="Pelechas, Eleftherios" sort="Pelechas, Eleftherios" uniqKey="Pelechas E" first="Eleftherios" last="Pelechas">Eleftherios Pelechas</name></noRegion><name sortKey="Drosos, Alexandros A" sort="Drosos, Alexandros A" uniqKey="Drosos A" first="Alexandros A" last="Drosos">Alexandros A. Drosos</name><name sortKey="Voulgari, Paraskevi V" sort="Voulgari, Paraskevi V" uniqKey="Voulgari P" first="Paraskevi V" last="Voulgari">Paraskevi V. Voulgari</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E69 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E69 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:6732515
|texte= Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:31564885" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |